Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Core Insights - Clairity, Myriad Genetics, and MagView have formed a collaboration to enhance breast cancer risk assessment for women, aiming to fill a significant gap in identifying high-risk individuals without adding administrative burdens [1][2][7] Company Summaries Clairity - Clairity is an AI-powered precision health company that has developed Clairity Breast, the first FDA-authorized tool to estimate a woman's five-year breast cancer risk from a routine mammogram, focusing on prevention rather than detection [3][6] - The company aims to empower health systems and radiologists to act earlier in cancer care, potentially saving lives and reducing overall healthcare costs [3] Myriad Genetics - Myriad Genetics specializes in molecular diagnostic testing and precision medicine, offering tests that assess disease risk and guide treatment decisions, thereby improving patient care and reducing healthcare costs [4][6] - The integration of Myriad's MyRisk Hereditary Cancer Test with Clairity's AI-powered assessment is expected to provide clinicians with actionable insights for earlier and more personalized interventions against breast cancer [2][7] MagView - MagView is a leader in breast imaging workflow solutions, providing software that enhances mammography reporting and high-risk screening, utilized by over 2,500 facilities across the U.S. [5][6] - The Luminary Risk platform from MagView will integrate Clairity and Myriad's offerings, streamlining risk information capture and improving workflow efficiency for breast health management [2][5]